Indication
Acute bacterial skin and skin structure infections (ABSSSI)
Administration
Oral Administration
May take with or without food
IV Administration
Administer as IV infusion over 1 hr
Do NOT give as IV push or bolus
Not for intra-arterial, IM, IT, intraperitoneal, or SC administration
Adult Dose
Adult: 200 mg PO/IV once daily for 6 days
Hepatic impairment: No dosage adjustment required
Child Dose
<18 years: Safety and efficacy not established
Renal Dose
Renal impairment or hemodialysis: No dosage adjustment required
Contraindication
Contraindicated for patients with hypersensitivity to Tedizolid and ingredients
Mode of Action
Inhibits protein synthesis by binding with 50S ribosomal sub-unit in bacteria
Precaution
Patients w/ neutropenia (neutrophil counts <1,000 cells/mm3). Discontinue if C. difficile-associated diarrhoea (CDAD) is suspected or confirmed. Patients w/ concomitant complicated skin & soft tissue infection & secondary bacteremia & in treatment of ABSSSI w/ severe sepsis or septic shock; diabetic foot infections, decubitus or ischaemic ulcers, bone or joint infections, severe burns, necrotizing infections or gangrene. May affect ability to drive or operate machinery. Pregnancy & lactation. Childn <18 yr. Elderly ≥75 yr.
Side Effect
2-10%
Nausea (8%)
Headache (6%)
Diarrhea (4%)
Hemoglobin <10.1 g/dL (3.1%)
Vomiting (3%)
Platelets <112 x 10³/mm³ (2.3%)
Dizziness (2%)
<2%
Blood and lymphatic system disorders: Anemia
Cardiovascular: Palpitations, tachycardia
Eye disorders: Asthenopia, vision blurred, visual impairment, vitreous floaters
General disorders and administration site conditions: Infusion-related reactions
Immune system disorders: Drug hypersensitivity
Infections and infestations: Clostridium difficile colitis, oral candidiasis, vulvovaginal mycotic infection
Investigations: Hepatic transaminases increased, decreased WBCs
Nervous system disorders: Hypoesthesia, paresthesia, seventh nerve paralysis
Psychiatric disorders: Insomnia
Skin and subcutaneous tissue disorders: Pruritus, urticaria, dermatitis
Vascular disorders: Flushing, hypertension
Interaction
Increased AUC & Cmax of rosuvastatin. Inhibition of BCRP at the intestinal level, increased plasma conc of BCRP substrates, & the potential for adverse reactions especially for BCRP substrates w/ narrow therapeutic index (eg, methotrexate or topotecan), or rosuvastatin.